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A B S T R A C T
The last decade has seen a great proliferation of supervised learning pipelines for individual diagnosis and
prognosis in Alzheimer’s disease. As more pipelines are developed and evaluated in the search for greater
performance, only those results that are relatively impressive will be selected for publication.We present an
empirical study to evaluate the potential for optimistic bias in classiﬁcation performance results as a result of
this selection. This is achieved using a novel, resampling-based experiment design that effectively simulates
the optimisation of pipeline speciﬁcations by individuals or collectives of researchers using cross validation
with limited data. Our ﬁndings indicate that bias can plausibly account for an appreciable fraction (often
greater than half) of the apparent performance improvement associated with the pipeline optimisation,
particularly in small samples. We discuss the consistency of our ﬁndings with patterns observed in the
literature and consider strategies for bias reduction and mitigation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Alzheimer’s disease (AD) is probably the most studied applica-
tion of supervised learning in neuroimaging (Arbabshirani et al.,
2016; Klöppel et al., 2012; Orrù et al., 2012). Though AD progres-
sion is a continuous process, it is often approximated as a discrete
one, making predictive modelling into a classiﬁcation task. This may
involve distinguishing AD subjects from healthy controls (HC), or, in
a cohort of subjects suffering from mild cognitive impairment (MCI),
distinguishing subjects who will progress to a full dementia diag-
nosis (MCIp) from those who will not (MCIs). This last task is of
particular relevance, as the identiﬁcation of subjects with expected
rapid decline aids the detection of therapeutic effects in clinical trials
(Klöppel et al., 2012).
* Corresponding author.
E-mail address: alexander.mendelson.11@ucl.ac.uk (A.F. Mendelson).
1 Data used in preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the
investigators within the ADNI contributed to the design and implementation of ADNI
and/or provided data but did not participate in analysis or writing of this report. A
complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
A supervised learning pipeline comprises some combination of
imaging, feature production, and supervised learning algorithm.
After nearly a decade of research (Klöppel et al., 2008), hundreds of
pipelines have already been developed and evaluated in the search
for superior performance (Arbabshirani et al., 2016; Falahati et al.,
2014; Mendelson). The ﬁeld has been greatly assisted by large open
access datasets provided by the Alzheimer’s Disease Neuroimaging
Initiative (ADNI), amongwhose key aims is the development of novel
diagnostic methods (Weiner et al., 2013). Indeed, in recent years the
vast majority of that research has been conducted using ADNI data
(Arbabshirani et al., 2016; Falahati et al., 2014).
The use of supervised learning necessitates some form of cross
validation (CV), broadly deﬁned as the use of separate training and
testing data (Arlot et al., 2010), to estimate predictive performance
(Lemm et al., 2011). When individuals or collectives evaluate mul-
tiple pipelines using CV on a limited dataset in search of greater
performance, it is inevitable that only relatively impressive results
will be selected for publication. As a consequence of this, reported
performance estimates will acquire a positive selection bias (Cawley
and Talbot, 2010). Because AD is one of the most well studied appli-
cations of supervised learning in neuroimaging, it is also likely to
be one of those where bias is most important. This bias should be
of great concern to pipeline researchers, as it will mean that their
results will fail to generalise. If a new pipeline is introduced into
http://dx.doi.org/10.1016/j.nicl.2016.12.018
2213-1582/ © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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diagnostic practice on the basis of upwardly biased performance esti-
mates and it actually fares worse than the system it replaces, then
there is even the potential for harm.
Selection bias is not unknown in medical imaging (Rao et al.,
2008), though the concept is often confused with the related phe-
nomenon of overﬁtting. It is now common knowledge that when
pipeline parameters are selected to maximise the full sample CV
performance estimate, the ‘optimised’ performance estimate will
acquire an optimistic bias (Arbabshirani et al., 2016; Kriegeskorte
et al., 2009; Lemm et al., 2011). We want to draw attention to
the fact that is not only pipeline parameters (e.g., the C of support
vector machines) whose selection using CV can incur bias, but entire
pipeline speciﬁcations (e.g., choice of features, algorithm); when the
research community collectively evaluates many pipelines on the
available data and selects the best results for publication, this is
directly analogous to the selection of parameters so as to maximise
performance. As such, the community should be aware of the poten-
tial of its published results to have acquired an optimistic bias.
This paper aims to assess the likely levels of selection bias in the
existing results of the literature and to assess the relative impor-
tances of the key contributory factors to assist in the reduction and
mitigation of bias in future. We consider the extent to which bias
may be responsible for the improvements in classiﬁcation perfor-
mance observed with pipeline optimisation. Because selection bias is
intimately related to the role of chance in determining the ranking of
pipelines’ CV performance estimates, we also consider the reliability
of CV experiments in determining which of two pipelines is superior.
To the best of our knowledge, no other study that has attempted to do
this for either AD classiﬁcation or any other application of supervised
learning in neuroimaging.
Before we describe our experiment and its implications, we shall
ﬁrst provide a clear deﬁnition of selection bias and its relationship to
overﬁtting.
2. Background
This section is concerned with providing a clear deﬁnition of
selection bias and describing the mechanisms by which it may arise
in AD classiﬁcation research.
2.1. The performance of a pipeline
In this work, we are interested in the performances of pipelines
themselves, rather than the performances of the fully speciﬁed pre-
diction rules they produce. For the sake of simplicity, we deﬁne
the performance of a pipeline to be the expected performance
measurement obtained in the cross validation experiment being
used, where the expectation is taken over many independent
samples. This deﬁnitions allows us to separate concerns related to
changes in training set size from those related to selection bias. For
our purposes, in the absence of selection, CV performance estimators
are by deﬁnition unbiased.
2.2. Introducing selection bias
The use of CV to select a high performing pipeline is directly anal-
ogous to the use of a single validation set to select a prediction rule
(e.g., a regression curve) (Cawley and Talbot, 2010). In both cases,
some noisy in-sample performance estimate based on a ﬁnite sample
(e.g., CV accuracy measurement, in-sample mean squared error) is
used to approximate the true out-of-sample performance on a larger
population of items (e.g., true pipeline performance, expected mean
squared error). There is some pool of candidate pipelines/rules, from
which the one with the best in-sample performance estimate is
selected. In rule selection, the size of this pool is often described by
“model complexity” (Lemm et al., 2011).
The performance measurement for each candidate may be
regarded as the sum of its true, out-of-sample performance plus
a zero-mean random effect. Where random effects play a role in
determining the empirical ranking of the pipelines by their in-
sample performance estimates, the highest in-sample performance
estimate is more likely to be associated with a positive random
effect. (That is, the candidate with the highest in-sample perfor-
mance is likely to have been ‘lucky’ in the validation experiment.) As
a consequence of this, if the validation is repeated on an indepen-
dent sample, the pipeline selected as the best in the ﬁrst experiment
will, on average, performworse. The expected drop in performance is
the selection bias. The term ‘selection bias’ was ﬁrst used in the con-
text of prediction rule selection in Ambroise and McLachlan (2002).
It was borrowed by Cawley and Talbot (2010) to describe the related
phenomenon in pipeline selection. Selection bias may be considered
a form of, or analogous to, the publication bias seen in group dif-
ference studies and clinical trials (Button et al., 2013; Easterbrook
et al., 1991), as it describes the inﬂation of effects due to selective
reporting.
Selection bias is related to, but distinct from, the related phe-
nomenon of overﬁtting. Overﬁtting properly describes the situation
where a pool of candidate pipelines/prediction rules considered for
selection is expanded to provide more potential for improvement,
but where this expansion actually leads to the selection of a candi-
date with an inferior out-of-sample performance than was the case
before the expansion (Cawley and Talbot, 2010). This may be con-
trasted with selection bias, which is simply the expected difference
between the in-sample and out-of-sample performances associated
with a selected candidate. As illustrated in Fig. 1, while selection bias
is necessary for overﬁtting, it also occurs in regular ‘ﬁtting’. Fig. 1may
be viewed as an inversion of the more commonly seen illustration
describing the relationship between error (or negative performance)
and model complexity (related to candidate pool size), exempliﬁed
by Fig. 7 of Lemm et al. (2011).
2.3. Origins of selection bias in AD classiﬁcation
Naked “double-dipping”, or the reporting of the in-sample perfor-
mance estimate after it has been used to select continuous pipeline
number of candidate pipelines or prediction rules
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Fig. 1. Illustration of expected in-sample and out-of-sample performances in pipeline
or prediction rule selection. Selection bias is present as soon as there are multiple
candidates. This may be contrasted with overﬁtting (i.e., deterioration in the out-of-
sample performance), which only occurs once the number of candidates exceeds some
optimal value.
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parameters (e.g., support vector machine regularisation), has long
been recognised as unacceptable practice (Kriegeskorte et al., 2009;
Lemm et al., 2011). However, it is not only pipeline’s parameters
whose selection may introduce bias, but whole pipeline speciﬁcations
(e.g., choice of features, algorithm).While publishedworks often pro-
ceed as if each new pipeline was fully speciﬁed in complete isolation
from the data, this is often likely to be a ﬁction; in practice, because
data are limited, research groups will inevitably reuse subjects as
they evaluate sequential pipelines ideas. Years after proof of concept,
new AD classiﬁcation pipelines are only likely to be of widespread
interest if they deliver improvement over state-of-the-art alterna-
tives, and relatively unimpressive results are unlikely to appear in
new publications.While some of the selectionmay occur through the
rejection of manuscripts in review, the situation is likely to be more
similar to that seen in clinical research, where the most common
reason that unimpressive (non-signiﬁcant) results go unpublished
is that they are never even submitted for publication in the ﬁrst
instance (Easterbrook et al., 1991).
Selection can occur not only at the level of an individual research
group, but at the level of an entire research ﬁeld. The large collections
of imaging data required for AD classiﬁcation experiments are far
too costly for each new study to reproduce. These are expensive and
time consuming to produce, so it is not possible for each new study
to use a new, independent dataset. Instead, studies typically draw
data from large, open access repositories of the type provided by
ADNI (Weiner et al., 2013). Indeed, in recent years, the vast majority
of AD classiﬁcation studies have used overlapping subsets of the
ADNI dataset (Arbabshirani et al., 2016; Falahati et al., 2014). Where
studies share data, they also share some of the random effects in
CV performance estimation. This makes it possible for uncharacter-
istic performance results with large random effects, such as those
produced by extensive selection, to be repeatable across studies.
As the research community collectively evaluates new pipelines on
the shared dataset to select the best for publication, it simulates the
bias producing behaviour of the individual research group. This is the
second challenge identiﬁed by Nowotny,2 who primarily considers
classiﬁcation in the MNIST dataset. It is recognised in the design of
the Kaggle machine learning challenges,3 where it is dealt with by
using a second validation dataset that is kept hidden until the end of
the challenge.
3. Materials and methods
The organisation of the materials and methods is as follows: in
Section 3.1, we describe the ADNI subjects and images we used; we
then describe how we build our pipelines in Section 3.2 and the
design of our experiments in Sections 3.3 and 3.4.
3.1. Subjects and imaging data
All imaging and clinical data were obtained from the ADNI
database. A detailed description of them is provided in Appendix A.
In this study, we use T1-weighted structural magnetic resonance
images from the baseline time-point alone. This is the most com-
monly encountered imaging setting in AD classiﬁcation research
(Arbabshirani et al., 2016; Falahati et al., 2014), in part because it
is one of the most easily achievable in clinical practice. Each image
underwent the full pre-processing offered by ADNI for the rele-
vant scanner type. This includes corrections for distortions due to
gradient non-linearity (GradWarp) and corrections for additional
image intensity non-uniformities (B1 correction and N3 histogram
2 Note that Nowotny uses ‘overﬁtting’ in a colloquial sense to indicate the mere
presence of selection bias.
3 https://www.kaggle.com/
peak sharpening). Phantom-based spatial scaling was applied to all
images. We conducted our own quality control assessment in addi-
tion to that provided by ADNI to cover subjects for whom no quality
assessments were available. Where back-to-back images were avail-
able for the baseline time-point, the one with the superior quality
score was selected.
The use of structural MRI alone allows us to have a larger total
sample, something that is particularly important to us because our
experiment design limits us to using less than half of the full number
of subjects in a single CV experiment, and we wish to retain real-
istic sample sizes for that step. To further increase the size of our
sample, we included images from both 1.5 and 3.0 Tesla scanners.
This is not unprecedented (Abdulkadir et al., 2011; Ota et al., 2015),
and it may be a sensible option for future diagnostic tools in clinical
practice where the losses in performance due to heterogeneity may
be outweighed by the gains due to increased training sample sizes
(Abdulkadir et al., 2011). The inclusion of different ﬁeld strengths
may introduce small systematic differences between the represen-
tations of disease groups when they contain different proportions of
images derived from each ﬁeld strength, but we believe these should
be negligible in our case (see Section 5.3).
Suitable baseline images were available for a total of 1437 sub-
jects, and all of these underwent processing. For the purposes of this
study, MCI subjects were considered stable if they had an assess-
ment up to or beyond the subsequent 24 months follow-up period
in which they were not given a diagnosis of AD. MCI subjects were
considered progressive if they were given a diagnosis of AD at any
point during the follow-up period. MCI subjects whose progression
status could not be determined were excluded from the sample used
for experiments. Subjects with suspected dementia aetiologies other
than AD were excluded from our classiﬁcation experiments. This
yielded 372 HC subjects, 252 AD subjects, 230 stable MCI subjects
(MCIs) and 135 progressive MCI subjects (MCIp).
3.1.1. Further image processing
A sample speciﬁc group template was created using iterative
aﬃne and then B-spline registration using the publicly available
NiftyReg package.4 Tissue segmentation and atlas propagation algo-
rithms (more details in Sections 3.2.2 and 3.2.3 respectively) were
applied to all images in their native space. Tissue segmentations
and atlas labels were propagated to the space of the group tem-
plate. Group templates parcellations were produced by combining
the propagated labels of all 1437 available images by majority vote.
3.2. Pipelines
Due to the constraints of implementation and computational
time, it would not have been possible for us to include many of
the highest performing classiﬁcation pipelines from the literature.
Instead, we have tried to produce a large but plausible set of
pipelines based on pairings of one of the 48 feature sets described in
Section 3.2.1 and one of the 6 classiﬁcation algorithms described in
Section 3.2.6. Because one of the algorithms (random forest) cannot
be combinedwith 24 of the (kernel-based) feature sets, there are 264
pipelines in total.
3.2.1. Feature sets
We produce our 48 features sets in the same combinatorial way
that we produce our pipelines. Each feature set is a combination of
some imaging descriptor (see Section 3.2.2), one of two anatomical
parcellation schemes to interpret that descriptor (Section 3.2.3), and
some way of using that scheme to perform a knowledge-based fea-
ture selection (Section 3.2.4). All imaging descriptors were produced
4 http://cmictig.cs.ucl.ac.uk/wiki/index.php/NiftyReg
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using no more than one of the two grey matter (GM) tissue concen-
tration maps (see Section 3.2.2) and one of two anatomical parcel-
lation schemes (see Section 3.2.3). Note that not all combinations of
options were possible.
3.2.2. Imaging descriptors
GM concentration maps are one of the most fundamental tools
for the study of structural changes in the brain; they have a key
role in the voxel-based morphometry that has become the estab-
lished tool for group difference studies in structural neuroimaging.
They were the ﬁrst image descriptors considered for AD classiﬁca-
tion (Klöppel et al., 2008), and they are still studied frequently (Bron
et al., 2015; Ota et al., 2015).Wherewe do not use GM concentrations
to produce descriptors, we use the volumes of whole anatomical
regions as descriptors themselves. Though these are used less often
than GM measures, these also provide a straightforward description
of brain atrophy that can be used to classify neurological diseases
(Keihaninejad et al., 2012).
We can divide the imaging descriptors into two groups: primal
descriptors representing the values of a quantity in each region
of an anatomical parcellation in the native space, and dual or
kernel descriptors represented by kernel matrices computed from
voxelwise intensity scores in the groupwise space.
Primal descriptors. Regional GM loads were calculated by summing
tissue concentrations over regions of the anatomical parcellations
in the native space multiplied by the volume of the voxels. This
produces descriptors that reﬂect changes in both the volume and
concentration of GM. All GM loads were normalised for intra-cranial
volumemeasured as the union of the white matter, GM and cerebro-
spinal ﬂuid tissue maps produced by SPM.
SPM GM loads. We use the publicly available SPM12 package5 to
provide tissue concentrations maps.
GIF GM loads. The geodesic information ﬂow (GIF) algorithm
(Cardoso et al., 2012) used to produce the Neuromorph par-
cellations (see Section 3.2.3) jointly estimates various tissue
concentrations maps. We included the resulting GM maps as an
alternative to those of SPM.
Anatomical region volumes. The volumes of anatomical regions
were normalised by intra-cranial volume.
Kernel descriptors. All kernel descriptors were produced from either
GIF or SPM GM maps after transformation to the groupwise space.
Kernel matrices were computed separately for each region of the
group parcellation and then later combined by summation. There
were three levels of further processing possible in the groupwise
space, producing a total of six kernel descriptors.
1. No further processing as the simplest option.
2. Modulation by the Jacobian determinant of transform from
the native to the groupwise space.
3. Smoothing (performed in addition to modulation) using an
isotropic Gaussian kernel of 2.0 mm standard deviation (4.7
mm FWHM). This aims to compensate for registration errors
and the spatial variation of atrophy patterns. The use of 2.0 mm
was intended to be a middle-of-the road choice.
3.2.3. Anatomical parcellation schemes
Due to its impact on the features produced, the choice of anatom-
ical parcellation scheme can be an important determinant of a
5 http://www.ﬁl.ion.ucl.ac.uk/spm/doc/
pipeline’s performance (Ota et al., 2015). We include two parcella-
tion schemes in our feature sets. These were chosen because they
were the only ones for which we were able to obtain the sets of
manually labelled images necessary for reliable atlas propagation
(Cardoso et al., 2012).
Hammers. This is a scheme of 83 regions described in Gousias
et al., (2008), Hammers et al. (2003), with 30 manually labelled
reference images available online.6 The labels of these images
were propagated to the space of our images and fused using the
STEPS algorithm (Cardoso et al., 2013).
Neuromorph. This is a scheme of up to 141 brain regions pro-
vided by the commercial company Neuromorphometrics, Inc.
under academic subscription. We use 35 labelled reference
images originating from the OASIS project that were made avail-
able for the MICCAI 2012 Grand Challenge and Workshop on
Multi-Atlas Labeling.7 These were propagated and fused using the
GIF algorithm (Cardoso et al., 2012).
Each scheme offers a competing deﬁnition of what precisely con-
stitutes an anatomical region in the brain. This in turn determines
which areas of the brain will be used in predictive modelling. A
notable difference between the two schemes is the way in which
cortical regions are deﬁned. In the Hammers scheme, many regions
combine both the relevant cortical grey matter and the cerebral
white matter beneath. By contrast, in the Neuromorph scheme, cere-
bral white matter and cortical grey matter are held in separate
compartments.
3.2.4. Spatial restriction/feature selection
The selection of relevant features can be used to remove vari-
ability in the data unrelated to the class discrimination problem.
Knowledge-driven feature selection techniques have been shown to
be superior to data-driven ones (Chu et al., 2012), and they have the
added advantage of being computationally inexpensive. We consider
two types of spatial restriction that implement a knowledge-driven
feature selection.
A symmetry constraint enforced by combining, as an average,
each pair of features related to a brain region occurring in each
hemisphere. While the atrophy associated with AD may not
be symmetric (Shi et al., 2009), the modes of atrophy that are
most informative for classiﬁcation may be. Due to the diﬃculty
establishing a voxel-to-voxel correspondence between the hemi-
spheres, the constraint was not applied to kernel-based feature
sets.
An exclusive focus on the temporal lobes justiﬁed by their well
established role in AD (Braak and Braak, 1991; Frisoni et al., 2010).
Zero, one, or both of these were applied to produce a feature set.
3.2.5. Standardisation
All kernels were scaled so that the median inter-point distance
in the whole sample was one. This scaling is mentioned because
of its interaction with the C parameter in the SVM algorithm (see
Section 3.2.6). All primal features were standardised by subtraction
and division to ensure a zero mean and a unit variance.
3.2.6. Classiﬁer algorithms
Unless otherwise stated, all classiﬁer algorithms were imple-
mented in C++ by the authors.
6 http://brain-development.org/brain-atlases/
7 https://masi.vuse.vanderbilt.edu/workshop2012/index.php/Main_Page
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SVM. The support vector machine (SVM) is the workhorse of
neuroimage classiﬁcation research (Kambeitz et al., 2015; Orrù
et al., 2012), and is by a wide margin the most studied algorithm
in applications related to AD (Falahati et al., 2014). We use the
publicly available libsvm package (Chang and Lin, 2011) with
a linear (precomputed) kernel, as is commonly preferred for
the high dimensional classiﬁcation problems of neuroimaging
(Orrù et al., 2012). The C parameter was selected from the val-
ues 2−2, 2−1, · · · , 24 using nested two-fold CV with ﬁve repeats.
Results in preliminary experiments were essentially identical if
the range of C values considered was expanded.
RF. The random forest (RF) classiﬁcation algorithm is based on an
ensemble of decision trees (Breiman, 2001). RF has been applied
in AD classiﬁcation (Falahati et al., 2014; Gray et al. 2013), as well
as elsewhere in neuroimaging (Kambeitz et al., 2015). We follow
the original speciﬁcation by Breiman (2001) with the parameter
mtry set to the rounded square root of the number of features.
We used 100 trees. Increasing this number in preliminary exper-
iments produced essentially identical results. As we know of no
established way to apply RF to kernel features, combinations of
the RF algorithm and kernel feature sets do not appear in our ﬁnal
set of pipelines.
LDA1. Linear discriminant analysis (LDA) classiﬁcation has been
used frequently in AD classiﬁcation (Arbabshirani et al., 2016;
Falahati et al., 2014), though less often than SVM. LDA is based on
the projection of the data onto a single direction chosen to max-
imise the ratio of the between-class variance to the within-class
variance. This variance is estimated using the assumption that the
distributions of both classes have identical variance. For primal
feature sets only, the Ledoit-Wolf lemma (Ledoit and Wolf, 2004)
was used to provide a shrinkage estimator of the covariance. The
threshold used for classiﬁcation was based on a Gaussian model
using class prior probabilities derived from the training set.
LDA2. This is an alternative version of LDA where the full sample
covariance matrix is used, rather than the sum of the covariance
contributions from each of the subject groups. This produces
a biased, but slightly more stable estimator of the covariance.
We have found this to fare better than LDA1 in synthetic high
dimensional problems.
NC. The nearest centroid (NC) algorithm can be seen as something
of a ‘control’ for the more complex linear methods (LDA, SVM),
as comparison will show how important the estimation of the
covariance structure is. This algorithm assigns unseen points the
class whose distribution has the closest centre as estimated using
the training data.
KNN. The K-nearest neighbours (KNN) algorithm assigns a class
to each unseen subject based on the most common class among
the K nearest subjects in the training data. Though it is very
simple, KNN produces a ﬂexible prediction model that can have
high performance when the number of training examples is suf-
ﬁciently high. Because the distances between points may be
obtained straightforwardly from the kernel matrix, KNN may be
applied to kernel-based problems. The number of neighbours was
selected using nested two-fold CV with ﬁve repeats from the set
of odd numbers less than one third of the size of the training set.
3.3. Cross validation and performance measurement
We consider repeated stratiﬁed K-fold CV as an estimator of
pipeline performance. The numbers of subjects that appear in each
foldaredeterminedexactlyas in thepubliclyavailable libsvmpackage
(Chang and Lin, 2011). By R×Kcv, we denote K-fold CV with R repeats.
The performance measure from a single repetition of K-fold CV
is assessed using the classiﬁcation accuracy, deﬁned as the fraction
of subjects correctly classiﬁed. This is probably the most commonly
reported performance metric for AD classiﬁcation (Arbabshirani
et al., 2016; Bron et al., 2015; Falahati et al., 2014).
3.4. Resampling experiment design
In order to estimate the bias associatedwith selection of pipelines
based on performance, one needs to obtain both biased and unbiased
performance estimates. To do this, we use the resampling design
described in Fig. 2 and deﬁned below.
1. Two disjoint subsamples, respectively left and right, of a spec-
iﬁed sample size and class composition are drawn randomly
andwithout replacement from the full set of available samples.
2. Some form of (repeated) K-fold CV is applied to estimate the
performance of the pipelines in the left and right subsamples
separately. All pipelines are compared in parallel alongside one
another.
3. The pipelines are ranked by their performance in the left
dataset. The nth ranked performance measurement in the left
dataset (henceforth, the in-sample estimate) is a biased esti-
mator for the performance of the pipeline that obtained that
rank (see Section 2.2), but the corresponding measurement in
the right dataset (henceforth, the out-of-sample estimate) is
not. The difference between the two is an (unbiased) estimator
for the selection bias associated with the nth rank position.
4. The last step is repeated, but this time the roles of the left and
right datasets are reversed. The average of the two resulting
bias estimates is taken.
This process is repeated 2000 times using different random parti-
tions into left and right subsets, and the bias estimates are averaged
together to provide greater stability.
We use this design to investigate two classiﬁcation tasks: the dis-
crimination of subjects with AD from healthy controls (henceforth,
biased 
L
unbiased 
R
2.
1.
- =
bias est. 
-
+
+
3.
Fig. 2. One iteration of the full experiment design described in Section 3.4. In step 1,
two disjoint subsets labelled left and right are drawn from the full available dataset. In
step 2, some form of CV is used to produce two independent performance estimates
for a number of pipelines. In step 3, these are ranked by their values in the left subset.
The difference between the two estimate sets is then taken as an estimator of the bias
associated with the different rank positions.
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Fig. 3. Illustration of the effect of ranking on performance estimation.
AD detection), and the discrimination of MCI subjects who went on
to progress to AD in a 24 month interval from those who did not
(henceforth, MCI prognosis). Both tasks are conducted in samples
containing only the two subject classes to be discriminated.
In order to investigate the effects of sample size and CV strategy,
we repeat this experiment procedure many times while varying
these parameters. When varying the sample size used for the
left/right subsamples, we keep the ratio of positive and negative
classes ﬁxed at 2:3, a ratio which closely approximates that in the
full available sample for both tasks (see Section 3.1). For AD detec-
tion, a subsample of size 50 will have 20 AD subjects and 30 controls.
Similarly, for MCI prognosis, a subsample of size 50 will comprise
20 progressive subjects, and 30 who remained stable. Under this
class balance constraint, sample sizes are varied from 30 up to
the maximum permitted by the full available sample in steps of
10. We repeated all experiments using R×Kcv strategies with K ∈
{1, 2, . . . , 24} and R ∈ {1, 2, . . . , 24/K}.
3.4.1. Number of pipelines considered
We investigate the effect of the number of pipelines considered
on selection bias. The probability of the pipeline obtaining the rank
p out of n (with p = 1 denoting the lowest performance) being
ranked the highest out of j pipelines selected randomly without
replacement is
Phighest of j =
(
n − p
j− 1
)(
n
j
)−1
. (1)
By using this formula to combine the biases associated with all n
ranks, we are able to measure the average in-sample and out-of-
sample performances associated with the best performing pipeline
over all
(
n
j
)
possible pipeline subsets.
We measure the progress associated with increasing the pool of
candidate pipelines as the change in performancewhenmoving from
a subset of a smaller size t one of a larger size. The change in in-
sample performance is the apparent progress anticipated based on a
naive interpretation of results, while the change in the out-of-sample
performance is the true progress expected on independent data.
3.4.2. Decision power and representative variance
Selection bias is intimately related to a CV experiment’s ability
to correctly identify the best of several pipelines. We produce two
summary measures to assess the ability of an experiment to do this.
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Fig. 4. Illustration of the relationship between the representative standard devia-
tion of a difference in performance and the selection bias associated with the highest
ranking pipeline.
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Fig. 5. Effect of CV strategy and sample size on the selection bias associated with the highest ranking pipeline. The upper plots illustrate the effect of additional K-fold repetitions,
while the lower plots compare strategies with approximately equal computational cost.
The ﬁrst measure is the decision power, deﬁned as the posterior
probability that an experiment correctly ranks a pair of pipelines.
This is measured as the fraction of times that the in-sample per-
formance ranking of a pair of pipelines was the same as the ‘true’
ranking based on the performance in all experiments, conditional on
the absolute difference in in-sample performance estimates falling
into a certain interval. This was averaged over all
(
264
2
)
pairs. It
was intended to help answer the question “What is the probability
that pipeline A is actually better than pipeline B, given that pipeline
A performed X% better in a CV experiment?”.
The second measure was the representative standard deviation of
a pairwise difference in performance. For each pair of pipelines, the
variance of the in-sample performance was computed. The average
of all
(
264
2
)
variances was then taken as a single representative
variance for a difference in performance. The square root of this is
taken as the representative standard deviation.
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Fig. 6. Effect of sample size on the in-sample and out-of-sample performances of the highest ranking pipeline. The association of low sample sizes and high selection bias
introduces a paradoxical effect where smaller sample sizes can lead to greater apparent (in-sample) performance.
4. Results
Where the curves of multiple sample sizes appear in the plots
of this section, these have been selected to display a representa-
tive range of behaviours. Where a single CV strategy is presented,
this is 4×6cv. This was chosen for its relatively low bias and its
intermediate fold number relative to the other strategies considered.
Where both in-sample and out-of-sample accuracies are presented,
the former is biased, while the latter can be regarded as accurate.
4.1. Accuracy of pipelines
We obtained a wide range of average pipeline performances in
each combination of task, sample size, and CV strategy. We report
the mean accuracies observed using 4×6cv and the maximum pos-
sible sample size for each task, as this produces the conﬁguration
most typical of the literature. For AD detection experiments on 300
subjects, the average performances of the pipelines spanned the
range 70–90%. For MCI prognosis experiments on 300 subjects, the
average performances spanned the range 60–70%. These accuracies
are towards the lower end of the spectrum of published results
(Arbabshirani et al., 2016; Cuingnet et al., 2011; Falahati et al., 2014;
Weiner et al., 2013). A more detailed description of these mean
performance results is presented in Appendix B.
4.2. Effect of rank on bias
Fig. 3 presents the expected in-sample (apparent) and out-of-
sample (true) performances associated with the different in-sample
rank positions in 4×6cv. The selection bias associated with a rank
position is the difference between its in-sample and out-of-sample
performances.
As expected, both in-sample and out-of-sample performances
increase with rank.8 The change in the in-sample performance is
greater, as the lower and higher ranks are respectively associated
with negative and positive selection biases. While higher perform-
ing pipelines are, on average, better than lower performing pipelines,
the magnitude of the difference is exaggerated by the in-sample
performance estimates. In AD detection, the exaggeration is rela-
tively small, and themajority of the observed difference in in-sample
performance is due to differences in the true, out-of-sample perfor-
mance. In MCI prognosis, the majority of the difference is due to
selection bias; for example, when using 160 subjects, the in-sample
difference between the highest and lowest performing pipelines was
on average roughly 16%, the out-of-sample difference between the
two was on average only roughly 6%.
It can be seen that smaller samples increase the magnitude of the
bias at all ranks. This effect is large enough to mean that the high-
est in-sample performance in MCI prognosis is higher when using
50 subjects than when using 160.
4.3. Variance as a determinant of bias
Fig. 4 plots the relationship between the representative stan-
dard deviation of a pairwise difference described in Section 3.4.2 and
the bias associated with the highest ranking in-sample performance.
Every sample size and experimental setting is represented by a
point. The almost linear relationship demonstrates that variance in
performance estimation is a key determinant of bias.
8 The in-sample performance estimates are themselves used to determine the
ranks. If the out-of-sample performance estimates did not also increase with rank,
this would mean that poor performance in a CV experiment was indicative of good
performance in future experiment repetitions.
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4.4. Bias as function of CV strategy and sample size
Fig. 5 illustrates the relationship between CV strategy, sample
size, and the bias associated with the highest ranking pipeline.
Through its effect on variance, sample size is an important deter-
minant of bias, with bias being approximately proportional to its
inverse square root. It can be seen that, for a given sample size and
CV strategy, MCI prognosis is associated with greater bias than AD
detection. In the upper plots, it can be seen that using additional
K-fold CV repetitions decreases bias, though the returns diminish
rapidly with the number of repetitions. The low value of K was
selected because smaller values lead to more dramatic variance
reduction with repetition. The lower plots compare CV strategies
using equal train-test cycles, indicative of roughly equal computa-
tional effort. It can be seen that accepting a lower number of folds to
produce a higher number of repetitions reduces bias appreciably.
In Fig. 6, we present the relationship between sample size and
the performance of the highest ranking pipeline. It can be seen that,
through its effect on training set size and better pipeline selec-
tion, larger samples lead to higher true, out-of-sample performance.
While this improvement will to some degree be reﬂected in the
in-sample performance, there is also an unexpected effect; because
increasing sample size reduces selection bias (the difference between
in-sample and out-of-sample performances), it can actually lead to a
drop in the apparent (in-sample) performance of the highest ranking
pipeline. This effect only occurs at smaller sample sizes in AD detec-
tion. In MCI prognosis it is so large that it completely overwhelms
the improvement expected due to the increase in the out-of-sample
performance, and all the best in-sample performances are observed
at low sample sizes. The use of a lower variance CV strategy (e.g.,
with more repetitions) decreases the in-sample performance esti-
mate by reducing bias, but increases the out-of-sample performance
by allowing for a better identiﬁcation of a truly superior pipeline.
4.5. Real and apparent progress in pipeline optimisation
Fig. 7 illustrates the relationship between the number of pipelines
considered, denoted j, and the in-sample and out-of-sample perfor-
mances of the highest ranking pipeline. As described in Section 3.4.1,
this is an average taken over all subsets of pipelines. The results of
this ﬁgure may be compared with the theoretical model of Fig. 1.
When only one pipeline is considered, both in-sample and out-
of-sample performances are the same, as there is no selection bias.
As the number of pipelines considered increases, we can see the out-
of-sample performance increase as the degree of opportunity for real
improvement grows. The in-sample-performance of the best per-
forming pipeline grows at a much faster rate, reﬂecting the faster
growth of the selection bias. Both in-sample and out-of-sample per-
formances increase sub-logarithmically (at a quickly diminishing
rate). Though there is signiﬁcant selection bias, we observe no true
overﬁtting.
The change in performance seenwhen j increases from 1 to some
higher number represents the expected improvement in the per-
formance of a selected pipeline seen when expanding the pool of
candidate pipeline considered for selection from a single pipeline to
the larger number. The change in the in-sample performance repre-
sents the apparent progress seen on the data used for selection, and
the change in the out-of-sample reﬂects the true progress that would
be repeatable on independent data. As can be seen in both halves of
Fig. 7, while some of the apparent (in-sample) improvement in per-
formance is due to real (out-of-sample) performance improvement, a
large fraction of it is also due to increasing selection bias, particularly
in MCI prognosis. Larger sample sizes are associated with lower bias
and a larger fraction of true improvement.
Fig. 8 considers the relationship between sample size, CV strategy
and the fraction of the progress associated with pipeline optimi-
sation that is repeatable. This is measured as the increase in the
out-of-sample performance observed when expanding the pool of
selectable pipelines divided by the increase in the in-sample per-
formance. It can be seen that smaller sample sizes, higher variance
cross validation strategies, and larger pools of candidate pipelines
are associated with lower true progress fractions. For MCI progno-
sis, the fraction of true progress never rises above 50%, indicating the
majority of the improvement observed when using CV to identify supe-
rior pipelines is illusory. For AD diagnosis, themajority of the apparent
improvement is repeatable for sample sizes over 150.
4.6. Reliability of CV performance rankings
Fig. 9 illustrates the relationship between the magnitude of a
pairwise difference in performance observed in a CV experiment,
and the decision power, deﬁned as posterior probability that the
two pipelines associated have been correctly ranked. As expected,
larger sample sizes dramatically increase the probability of a correct
ranking. Decision power was computed for intervals of width 0.01
between 0 and 0.4. Too few differences in performance with magni-
tude above 0.4 were observed to estimate decision power accurately
after that point.
Fig. 10 considers the minimum magnitude required of an
observed difference in performance to ensure a 95% posterior prob-
ability of a correct ranking. This was calculated as the lower end of
the ﬁrst interval to have a suﬃciently high decision power. If one
was not found, no point is plotted. It can be seen that low vari-
ance CV strategies and larger samples reduce the required difference.
We found these minimum magnitudes required to produce a reli-
able ranking surprisingly large. If they are representative of the ﬁeld,
they highlight the importance of gathering a large sample before any
pipelines are compared. We note that signiﬁcantly larger observed
performance differences are needed to reliably rank pipelines in MCI
diagnosis than in AD detection.
4.7. Comparison with literature
The nature of selective reporting makes it diﬃcult to assess the
level of bias in the literature directly. One exception to this is found
in challenges such as CADDementia (Bron et al., 2015), which report
both biased in-sample performance estimates and unbiased out-of-
sample performance estimates. As can be seen in Fig. 7 of the relevant
paper (Bron et al., 2015), all 29 contestants overestimated the accu-
racy of their submitted AD classiﬁcation predictors, with an average
bias of almost 20% accuracy. Though it was not based on AD classi-
ﬁcation, a similar pattern is apparent in the MICCAI 2014 machine
learning challenge,9 where all but two of the 48 submissions overes-
timated their performance. It should be noted that selection biasmay
be greater in challenges than in standalone studies, as researchers
may be less concerned about reporting biased performance esti-
mates where they know there will be an independent validation.
As seen in Fig. 6, selection bias can introduce a paradoxical effect
where smaller sample sizes are associated with higher estimated
performance. Larger sample sizes should allow for larger training
sets, meaning that they should be associated with greater perfor-
mance (Chu et al., 2012; Mendelson et al., 2014); if a negative
association is observed, this may be taken as evidence of selection
bias. This provides us with a way to look for selection bias in the AD
classiﬁcation literature. This is analogous to the use of funnel plots to
detect publication bias in group difference studies (Sterne and Egger,
2001).
9 https://competitions.codalab.org/competitions/1471
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Fig. 7. Effect of number of pipelines considered on the expected (biased) in-sample accuracy and (unbiased) out-of-sample accuracy associated with the highest ranking pipeline.
The in-sample curve represents the apparent progress associated with pipeline optimisation, while the out-of-sample curve represents the true progress. It can be seen that much
of apparent progress associated with an increasing number of pipeline options is spurious (i.e., due to increasing bias alone).
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the performance of the selected pipeline. It can be seen that this fraction never rises to above 50% in MCI prognosis.
To provide us with a representative set of reported AD
classiﬁcation results, we selected those from the recent review of
Arbabshirani et al. (2016) (see Table 2 of that paper). We selected
only those papers which advanced newmethods (and thus excluded
comparative studies such as Cuingnet et al. (2011)), and considered
results for AD detection and MCI prognosis. In order to avoid per-
forming additional selection ourselves, where a range of accuracies
is reported, we took the mean of the upper and lower estimates.
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Multi-modal studies tend to be associated with smaller samples
and higher performance. In order to avoid a spurious effect due to
smaller samples being associated with more informative modalities,
we included only those results achieved using structural MRI alone.
This yielded 55 performance estimates for AD classiﬁcation and 15
for MCI prognosis. These are presented in Fig. 11.
We conducted a one-sided test to assess the evidence against
a non-negative association. Because a Gaussian null hypothesis is
not appropriate, we used Spearman’s correlation coeﬃcient, rather
than Pearson’s. We observe a negative correlation in both AD detec-
tion and MCI prognosis. While the negative correlation is of greater
magnitude inMCI prognosis, it only reaches signiﬁcance in AD detec-
tion, due to the larger number of studies. We note that our test is
somewhat conservative, as the null hypothesis of no selection bias
actually corresponds to a positive rank association, rather than the
zero rank association used in signiﬁcance testing. We conclude that
there is tentative evidence of selection bias in the AD classiﬁcation
literature.
5. Discussion
We have provided the ﬁrst empirical demonstration of selec-
tion bias in AD classiﬁcation. While we saw no true overﬁtting, our
results demonstrate that bias can account for signiﬁcant fraction
of the apparent progress associated with pipeline optimisation (see
Fig. 8). In small samples and MCI prognosis experiments, the fraction
of progress attributable to bias was normally greater than 50%. The
potential existence of such great bias should be of signiﬁcant concern
to researchers, as pipelines brought into clinical practice on the basis
of overly optimistic results may lead to poor outcomes.
5.1. Controlling selection bias and mitigating its effects
Selection bias is principally controlled by variance in performance
estimation and the number of pipelines considered for selection (see
Figs. 4 and 7). Selection bias may be reduced by using low vari-
ance CV strategies. We recommend that a large number of K-fold CV
repetitions be used where computationally feasible. We recommend
against the use of high variance strategies such as leave-one-out
cross validation (LOOCV) (which is still used (Challis et al., 2015;
Coupé et al., 2012; Dai et al., 2012; Dukart et al., 2013; Padilla
et al., 2012)). Instead of using high numbers of folds, one can use a
lower number of folds with a higher number of K-fold CV repetitions
to produce a lower variance, lower bias CV strategy at equivalent
computational cost (see Fig. 5).
Maximising sample size is also important for the avoidance of
selection bias; selection bias is roughly proportional to the inverse
square of the sample size (see Fig. 5). This is likely due to its effect
on variance. We caution against any optimisation or comparison of
pipeline speciﬁcations in small samples, as this is unlikely to pro-
duce reliable identiﬁcation of superior pipelines (see Figs. 9 and 10),
and most of the apparent progress will be due to bias alone (see
Fig. 8).
Though it would be cumbersome to implement, a selection bias
free validation strategy does exist: one can treat the entire speciﬁ-
cation of a pipeline the same way one treats a continuous pipeline
parameter, and select it using nested cross validation (Cawley and
Talbot, 2010).While this provides an unbiased answer to the question
“how well can we predict?”, it may not provide an answer to the
question “what is the best way to predict?”. Outside of this, another
valuable source of bias free results comes from classiﬁcation chal-
lenges such as the recent CADDementia (Bron et al., 2015). Not only
do challenges provide unbiased performance estimates for individual
pipelines, but they can also offer an unﬁltered overview of the full
distribution of the performances of evaluated methods that may
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Fig. 9. Illustration of the decision power associated with 4×6cv in both classiﬁcation tasks. This is the probability that pipeline B is truly superior to pipeline A, given that B
performed X better than A in CV experiment, where X is the value of the x-axis. Horizontal bars represent calculation intervals. For i ∈ {1, 2, . . . , 20}, interval i contains difference
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A. Mendelson et al. / NeuroImage: Clinical 14 (2017) 400–416 411
50 100 150 200 250 300
0.00
0.05
0.10
0.15
0.20
0.25
40 60 80 100 120 140 160
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
8x3cv
4x6cv
2x12cv
1x24cv
Performance difference in AD detection Performance difference in MCI prognosis
number of subjects number of subjects
8x3cv
4x6cv
2x12cv
1x24cv
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be contrasted with the literature. We note that if the best result
in a challenge is selected, this reintroduces the potential for bias
(Nowotny).
It is not only important that future studies work tominimise bias;
the potential for bias must also be considered in the interpretation
of previous published results. This is particularly the case where a
result is linked with one of the following risk factors:
• the classiﬁcation task is diﬃcult (consider MCI prognosis ver-
sus AD detection);
• the sample used to demonstrate CV performance results is
small; or
• there is evidence indicative of extensive selection; for instance,
there are many adjustable settings in a pipeline, and there is
not clear explanation for how they have been chosen.
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Fig. 11. Summary of sample sizes and balanced accuracies from papers considered in Arbabshirani et al. (2016) using structural MRI alone. The selection of the studies and the
production of performance measures is described in Section 4.7. The variable rs denotes Spearman’s rank correlation, and the p values are derived from a one-sided test against a
non-negative rank association. N denotes the number of studies included in a tasks’ plot.
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That MCI prognosis is particularly susceptible to bias is trou-
bling, as AD classiﬁcation pipelines are primarily justiﬁed for the
superior performance they are ultimately supposed to offer in that
task. There are a number of other consequences of these considera-
tions. For instance, practitioners may prefer simpler pipelines with
fewer adjustable parameters over more complex alternatives, even
when the latter come with higher reported performance. Further-
more, while it might be assumed that the apparent advantage of
pipelines using alternative modalities instead of or in addition to
structural MRI is due to additional information in the features, it
is possible that some of it may be explained by the greater poten-
tial for selection bias afforded by the smaller samples available for
validation.
5.2. Particularly susceptibility of AD classiﬁcation to selection bias
AD classiﬁcation is not unique among other applications of super-
vised learning to neuroimaging in being liable to bias, but there
are good reasons why it may be particularly susceptible. The great
societal cost of AD provides a strong incentive for pipeline opti-
misation, and the availability of open access datasets has made it
considerably easier for researchers to contribute. As a consequence
of this, the number of published pipeline speciﬁcation is already in
the hundreds (Mendelson), making it comparable to or greater than
the size of a typical sample (Arbabshirani et al., 2016). While a larger
number of pipelines speciﬁcations (combinations of pre-processing,
feature selection, classiﬁcation algorithm) considered for selection
createsmore potential for genuine performance improvement, it also
creates more potential for bias.
5.3. Limitations
We do not provide a perfect simulation of the AD classiﬁcation
research ﬁeld, as this would be technically infeasible; as such, our
results should be interpreted as indicative rather than exact. Due to
the diﬃculty in accurately determining and then implementing the
full set of published research methods (registration, segmentation,
feature selection, etc.) we have instead opted for a more limited set
of relatively simple methods that nonetheless loosely representative
of the ﬁeld. Despite this, we still believe that our results are repre-
sentative, and we do not anticipate that small changes to the precise
combination of pipelines and CV strategies usedwould produce qual-
itatively different results.We note thatwhile the number of pipelines
considered for selection was large, it does not exceed the number
of those already published (Mendelson). While the ranges of sample
sizes considered do not include some of the largest numbers seen
in recent studies, they still include those seen in the majority of AD
classiﬁcation studies (Arbabshirani et al., 2016).
We note that most of the metrics provided here (e.g., selection
bias in a particular experimental setting) do not come with mea-
sures of measurement uncertainty. To produce these would require
a deep statistical model of the distribution of results produced in
our experiment, including a generative model for the distribution
of subject representations in features space. We note that the same
is currently lacking for even straightforward K-fold cross validation
(Bengio and Grandvalet, 2004). This should not be a great concern,
however, as the deviations due to randomness in our sample are
likely to be smaller than those associated with changes in precise
deﬁnitions of pipelines and experimental settings.
Variations in the ﬁeld strength used to produce a T1-weighted
image can have a subtle effect on the tissue concentration maps
and region volumes derived from it. In comparative studies where
subject groups contain different proportions of images from 1.5
and 3.0 Tesla scans, this may introduce spurious differences that
are unrelated to physiology. Though this effect is likely present
in our study, we do not think it is signiﬁcant. The fraction of
images acquired at 3.0 Tesla was relatively constant (between 31
and 48%) across disease groups (i.e., HC, MCIs, MCIp, and AD). Fur-
thermore, ﬁeld strength-related differences in tissue concentrations
and volume measures will be small compared to those related to
atrophy, and so seem unlikely to provide signiﬁcant improvements
to classiﬁcation accuracy. Indeed, we did not observe any unusu-
ally impressive results suggestive of such improvements. Finally,
we again note that our classiﬁcation experiments do not need to
precisely match the ﬁeld to be informative.
5.4. Population shift
We note that selection bias is distinct from the problem of pop-
ulation shift (or drift) (Hand et al., 2006), which occurs when the
feature representations of the subjects to be classiﬁed in the real
application of a pipeline have a different distribution to that of those
used in the validation sample. This is also likely to be a great chal-
lenge in the clinical translation of AD classiﬁcation methods, as they
must generalise to scanner types and patient populations that may
be unlike those in research settings (Abdulkadir et al., 2011), but it is
separate from the issues addressed here.
6. Conclusion
We have demonstrated that selection bias can plausibly account
for a considerable fraction of the progress associated with
pipeline optimisation in AD classiﬁcation. We remind classiﬁcation
researchers to be aware of the potential for bias in their own
work. Speciﬁcally, we encourage researchers to use low variance
(low K, high repetition) cross validation strategies, and caution
against pipeline optimisation or comparison before suﬃciently large
samples are available, as this will quickly produce misleading
performance results while providing little real improvement. We
also urge caution in the interpretation of published results; for MCI
prognosis in particular, our results suggest that typical sample sizes
provide great potential for bias. Before any published pipeline is con-
sidered for use in clinical decision making, it is imperative that the
potential for selection bias be taken into account. Finally, our results
highlight the importance of classiﬁcation challenges, which offer
a rare opportunity for the non-selective reporting of performance
results.
While this study focused on AD classiﬁcation, selection bias is a
potential problem for many similar applications of supervised learn-
ing in medical imaging. Our results may be useful to researchers in
other applications, as the determining factors and possible solutions
are likely to be the same.
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Appendix A. Imaging and clinical data
Imaging and clinical data were obtained from the ADNI database.
ADNI was launched in 2003 by the National Institute on Age-
ing, the National Institute of Biomedical Imaging and Bioengineer-
ing, the Food and Drug Administration, private pharmaceutical
companies and non-proﬁt organisations, as a $60 million, 5-year
public/private partnership. The primary goal of ADNI has been to
test whether serial MRI, PET, other biological markers, and clinical
and neuropsychological assessment can be combined to measure
the progression of mild MCI and early AD. Determination of sensi-
tive and speciﬁc markers of very early AD progression is intended
to aid researchers and clinicians to develop new treatments and
monitor their effectiveness, as well as lessen the time and cost of
clinical trials. The Principal Investigator of this initiative is Michael
W.Weiner, MD, VAMedical Center and University of California at San
Francisco. ADNI is the result of efforts of many coinvestigators from
a broad range of academic institutions and private corporations, and
subjects have been recruited from over 50 sites across the U.S. and
Canada. Up-to-date information on the initiative is available at www.
adni-info.com.
All subjects were designated as healthy control (HC), AD or MCI
at the time of the baseline scan, and were subsequently reassessed
at timepoints during follow-up. Inclusion criteria for HC subjects are
MMSE scores between 24 and 30, a CDR of 0, non-depressed and non-
demented. Ages of the HC subjects were roughly matched to those of
the AD and MCI subjects. For MCI subjects, the criteria are an MMSE
score between 24 and 30, a memory complaint, objective memory
loss measured by education adjusted scores on Wechsler Memory
Scale Logical Memory II, a CDR of 0.5, absence of signiﬁcant levels of
impairment in other cognitive domains, essentially preserved activ-
ities of daily living, and an absence of dementia. AD subjects were
identiﬁed by an MMSE score between 20 and 26, CDR of 0.5 or 1.0,
and the NINCDS/ADRDA criteria for probable AD.
Appendix B. Average performance of included pipelines
We present the average accuracy of the pipelines in the largest of the samples considered in the resampling design in Figs. B.13 and B.14.
A key to understanding these is presented in Fig. B.12. Note that the 3:2 ratio of negative (HC/MCIs) to positive (AD/MCIp) classes should give
a “null” accuracy of 60% for both tasks. Our design allows us to produce an unbiased variance estimate for the performance as estimated in
a single CV experiment (Mendelson et al., 2014). This in turn allows us to produce a very conservative (upwardly biased) estimate for the
variance of our ﬁnal performance estimate (by falsely assuming the average of all 2000 CV experiment pairs has the same variance as the
average of a single pair). This conservative estimate gives standard deviations in the range 1 to 3.5% for all accuracy estimates displayed in this
section. For the AD detection task (Fig. B.13) most of these are under 2%; for MCI prognosis (Fig. B.14), most of these are above 2%.
Though we present them primarily to demonstrate the plausibility of our methods, we can also make some comments on the accuracies
observed. These span a wide range in both tasks, with those in AD detection spanning the range 70–90%, and those in MCI prognosis spanning
the range 60–70%. This is towards the lower end of the spectrum of published results (Arbabshirani et al., 2016; Cuingnet et al., 2011; Falahati
et al., 2014; Weiner et al., 2013).
A loose hierarchy of classiﬁer algorithms is evident in the AD detection task, with SVM, LDA and RF consistently performing better than
Centroid and KNNwith a given feature set. This is not so much the case for MCI prognosis, where the ranking of algorithms is highly dependent
on the feature set. This may be due to the more diﬃcult nature of the task confounding the ﬁtting of more complex models. In both cases, clear
repeating patterns are visible, with GIF GM, SPM GM and region volumes producing similar results with the same regional restrictions.
Wh
sWh
Tl
sTl
H
N
Hammers atlas
NeuroMorph atlas
Whole brain
Whole brain (symmetric)
Temporal lobe
Temporal lobe (symmetric)
S GM
m S GM
sm S GM
G GM
m G GM
sm G GM
Vol
SPM Grey Matter
SPM Grey Matter (modulated)
SPM Grey Matter (modulated-smoothed)
GIF Grey Matter
GIF Grey Matter (modulated)
GIF Grey Matter (modulated-smoothed)
Region Volumes 
Imaging measure
Parcellation scheme
Spatial restriction
Fig. B.12. Key to accuracy Figs. B.13 and B.14. Each feature set is described by one label from each group.
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Fig. B.13. Average accuracies of AD diagnosis pipelines measured using 4×6cv and 300 subjects. See key in Fig. B.12.
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Fig. B.14. Average accuracies of MCI prognosis pipelines measured using 4×6cv with 160 subjects. See key in Fig. B.12.
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